Form 4: LENZ CFO Granted Significant Equity Compensation

LENZ Therapeutics' Chief Financial Officer, Daniel R. Chevallard, received grants of 84,200 stock options and 14,000 restricted stock units.

Summary

• Daniel R. Chevallard, Chief Financial Officer of LENZ Therapeutics, Inc. (LENZ), was granted equity compensation.
• The grants include 84,200 stock options with an exercise price of $16 per share.
• The grants also include 14,000 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock.
• Both the stock options and RSUs were granted on January 2, 2026.
• The stock options have an expiration date of January 1, 2036.
• Vesting for both awards is contingent on Mr. Chevallard continuing to be a Service Provider under the Issuer's 2024 Equity Incentive Plan.
• For stock options, 25% vest on the one-year anniversary of the Vesting Commencement Date (January 2, 2027), with the remaining shares vesting monthly (1/36th) thereafter.
• For RSUs, 25% vest on the one-year anniversary of the RSU Grant Date (January 2, 2027), with the remaining RSUs vesting every six months (1/8th) thereafter.

Sentiment

Score: 7

Explanation: The grant of equity compensation to a key executive is generally viewed positively as it aligns management's interests with long-term shareholder value. This is a routine disclosure of compensation, not a performance report.

Positives

• The grant of equity compensation to a key executive like the CFO aligns management's long-term interests with those of shareholders, incentivizing performance.
• The awards are part of the company's 2024 Equity Incentive Plan, indicating a structured approach to executive compensation.

Risks

• The vesting of both stock options and restricted stock units is contingent upon the Reporting Person's continued service as a 'Service Provider' to the Issuer.

Future Outlook

The equity grants are designed to incentivize the Chief Financial Officer's continued service and align his performance with the long-term success and shareholder value creation of LENZ Therapeutics.

Industry Context

The granting of stock options and restricted stock units to key executives is a standard practice across various industries, particularly in biotechnology and pharmaceutical sectors, to attract, retain, and motivate talent while aligning their interests with company performance and shareholder returns.

Comparison to Industry Standards

• Equity compensation, including stock options and RSUs, is a common component of executive compensation packages in the biotech industry, similar to practices at companies like Moderna, BioNTech, or Regeneron, which use such incentives to foster long-term commitment and performance.
• The vesting schedules (one-year cliff followed by monthly/bi-annual vesting) are typical for executive equity awards, designed to encourage retention over several years.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the CFO's interests with long-term shareholder value.
• Employees: No direct impact on general employees, but reflects the company's compensation strategy for key personnel.

Next Steps

• Daniel R. Chevallard must continue as a Service Provider to LENZ Therapeutics for the stock options and RSUs to vest according to their respective schedules.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a key executive, which is a standard compensation practice. It does not provide new financial performance data or strategic shifts that would significantly alter an investment thesis. Therefore, a 'hold' recommendation is appropriate as it doesn't present a compelling reason to change an existing position based solely on this filing.

Keywords

LENZ Therapeutics, LENZ, Form 4, SEC filing, stock options, restricted stock units, equity compensation, CFO, Daniel R. Chevallard, insider transaction, executive compensation